Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 16/20 | 0.35 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17690558 | 1.00 | FOLH1 (0.35) | FOLH1C3AR1TDP1FPR2 | |
| SCHEMBL13237046 | 0.98 | FOLH1 (0.36) | FOLH1 | |
| SCHEMBL15501039 | 0.97 | FPR2 (0.32) | FOLH1TDP1FPR2 | |
| SCHEMBL2835915 | 0.93 | FOLH1 (0.36) | FOLH1TDP1FPR2 | |
| SCHEMBL17685197 | 0.92 | FOLH1 (0.30) | FOLH1 | |
| SCHEMBL17685198 | 0.91 | — | — | |
| SCHEMBL13287694 | 0.90 | CTSK (0.31) | — | |
| SCHEMBL11936778 | 0.89 | — | — | |
| SCHEMBL2832354 | 0.89 | SIRT2 (0.37) | FOLH1TDP1 | |
| SCHEMBL2833226 | 0.87 | FOLH1 (0.32) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2706057-B1 | Bis(imidazolyl)compounds and radionuclide complexes | MOLECULAR INSIGHT PHARM INC (US) | 2016-04-20 | — | — | EP | claimed |
| EP-2706057-A1 | Bis(imidazolyl)compounds and radionuclide complexes | Molecular Insight Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | claimed |
| US-9433594-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433594-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2389361-B1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARM INC (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2389361-B1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARM INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| EP-2706057-B1 | Bis(imidazolyl)compounds and radionuclide complexes | MOLECULAR INSIGHT PHARM INC (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2706057-B1 | Bis(imidazolyl)compounds and radionuclide complexes | MOLECULAR INSIGHT PHARM INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8962799-B2 | Technetium—and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2706057-A1 | Bis(imidazolyl)compounds and radionuclide complexes | Molecular Insight Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8562945-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8562945-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8562945-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8211401-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | PSMA1, PSMA5, PSMA3 | FOLH1 4/4885C3AR1 4573/4885TDP1 3443/4885 |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | RAB35, SLC39A14, SLC39A3 | FOLH1 283/4885C3AR1 1536/4885TDP1 2624/4885 |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | SSTR5, SSTR3, SSTR4 | FOLH1 216/4885C3AR1 475/4885TDP1 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.